|
作用机制Abl family inhibitors [+19] |
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期2012-09-27 |
Regorafenib for Recurrent Grade 2 and 3 Meningioma. A Multicenter, Randomized Phase II Study (MIRAGE Trial)
The focus of this study will be to investigate whether Regorafenib demonstrates antitumor activity against recurrent grade II or III meningiomas.
Small trials and case series suggest clinical relevant activity of several VEGF inhibitors such as sunitinib, bevacizumab and valatinib reporting a 6m-PFS rate of 42-64%. Indeed, VEGF and VEGF receptors (VEGFR) are regularly overexpressed in meningiomas and can correlate with outcome.
Regorafenib inhibits angiogenic receptor tyrosine kinases (RTKs) and is highly selective for VEGFR1/2/3; moreover Regorafenib inhibits PDGFRB, FGFR1 and oncogenic intracellular signalling cascades involving c-RAF/RAF1 and BRAF highly expressed in meningiomas.
Noteworthy, Regorafenib showed antitumor activity in vitro and in vivo in a recent study; indeed, Regorafenib showed significant inhibition of meningioma cell motility and invasion and in vivo, mice with orthotopic meningioma xenografts showed a reduced volume of signal enhancement in MRI following Regorafenib therapy; this translated in a significantly increased overall survival time (p<0.05) for Regorafenib treated mice.
Moreover, Regorafenib showed good efficacy in different cancer types, such as colorectal cancer, GIST, hepatocellular carcinoma and glioblastoma (REGOMA trial) , maintainingmaintaining a good quality of life.
Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.
To learn if regorafenib can help to control the disease.
A Single-center, Single-arm, Exploratory Clinical Study of Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With PD-L1 Plus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma After Immunotherapy Failure.
For patients with advanced liver cancer who have progressed after first-line targeted and immunotherapy , there is currently no standard treatment regimen for second-line therapy. this study aims to explore the efficacy and safety of HAIC combined with PD-L1 and Regorafenib in patients with advanced liver cancer who have failed immunotherapy, not only providing new treatment options for second-line therapy of liver cancer, but also laying the foundation for research on the combination of HAIC and PD-L1 inhibitors plus Regorafenib, which has significant scientific research significance and clinical value.
100 项与 FGFR2 x RET x c-Kit x PDGFRβ x PDGFRα x FGFR1 x CSF-1R x FRK x BRAF x Tie-2 x DDR2 x VEGFR2 x CRAF x TRKA x VEGFR1 x BRAF V600E x EphA2 x Abl family x MAPK11 x VEGFR3 相关的临床结果
100 项与 FGFR2 x RET x c-Kit x PDGFRβ x PDGFRα x FGFR1 x CSF-1R x FRK x BRAF x Tie-2 x DDR2 x VEGFR2 x CRAF x TRKA x VEGFR1 x BRAF V600E x EphA2 x Abl family x MAPK11 x VEGFR3 相关的转化医学
0 项与 FGFR2 x RET x c-Kit x PDGFRβ x PDGFRα x FGFR1 x CSF-1R x FRK x BRAF x Tie-2 x DDR2 x VEGFR2 x CRAF x TRKA x VEGFR1 x BRAF V600E x EphA2 x Abl family x MAPK11 x VEGFR3 相关的专利(医药)